Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Valganciclovir preemptive therapy versus valacyclovir prophylaxis for cytomegalovirus after renal transplantation
ACTRN12610000015044Phase 4Completed
- Sponsor
- Tomas Reischig, M.D., Ph.D.
- Start
- Oct 2003
- Modality
- Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of valganciclovir and valaciclovir in cytomegalovirus disease (CMV) (2 arms), sponsored by Tomas Reischig, M.D., Ph.D. Primary endpoints: Cumulative incidence of cytomegalovirus disease, Acute rejection and 1 more. Started Oct 2003; status: completed.
02
Drugs
valganciclovirvalaciclovir
03
Conditions
cytomegalovirus disease (CMV)
Beyond the preview
Go deeper on ACTRN12610000015044.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12610000015044.